Immersive cardiac training tech gaining ground in high-stakes procedures

Tern plc

Fundamental XR is emerging as a key player in the shift toward immersive clinical training, offering a multimodal platform designed specifically for intracardiac interventions. Instead of relying on flat-screen visuals or isolated device simulations, this system merges real-world imaging modalities, including ultrasound, CT, fluoroscopy and 3D reconstructions, into a single virtual or mixed reality environment.

This matters because traditional training models are struggling to keep up with the demands of structural heart procedures. These interventions are becoming more intricate, with tighter tolerances and rising expectations around safety and efficiency. Platforms like Fundamental XR offer hospitals and manufacturers a tool to accelerate operator readiness, reduce avoidable errors, and improve procedural consistency, all of which are directly relevant to long-term value creation in this space.

What differentiates this model is its integration of full procedural context. Trainees don’t just learn isolated movements — they simulate the entire sequence of an intracardiac case, complete with real-time feedback from multimodal imaging. That creates a more realistic environment to develop the subtle spatial and tactile judgment needed for safe catheter navigation and device deployment. It also shortens the learning curve for new devices, which is increasingly important as manufacturers push for faster adoption cycles.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Tern invests £78,000 in Device Authority through 8% convertible loan notes

Tern Plc has committed approximately £78,000 to new convertible loan notes issued by Device Authority, which carry 8% annual...

Device Authority highlights security risks as AI begins controlling physical machines

Device Authority examines the security risks of AI-controlled machinery and the role of device identity, authentication and access controls...

Talking Medicines targets better pharmaceutical launch results through message analysis

Talking Medicines' Message Resonance Score measures doctors' understanding of pharmaceutical messaging to help companies improve launch strategies....

Search